The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
 
Daniel Peter Petrylak
Consulting or Advisory Role - Genentech; Lilly; Sanofi
Research Funding - Genentech; Lilly; Sanofi
Travel, Accommodations, Expenses - Genentech; Sanofi
 
Thomas Powles
Honoraria - Roche Pharma AG
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Fadi S. Braiteh
Employment - US Oncology
Stock and Other Ownership Interests - Celgene; Insys Therapeutics
Honoraria - Amgen; BIND Therapeutics; Caris Life Sciences; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Consulting or Advisory Role - Amgen; BIND Therapeutics; Caris MPI; Dendreon; Foundation Medicine; Incyte; Insys Therapeutics; MolecularHealth; Novartis; Pfizer; Saladax Biomedical; Sanofi
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Genomic Health; Incyte; Insys Therapeutics; Myriad Genetics; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Active Biotech (Inst); Amgen (Inst); Bayer (Inst); BIND Therapeutics (Inst); Biomarin (Inst); bioTheranostics (Inst); BN ImmunoTherapeutics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); Celgene (Inst); Cell Therapeutics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Foundation Medicine (Inst); Genomic Health (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); HERON (Inst); ImClone Systems (Inst); Insys Therapeutics (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); MEI Pharma (Inst); Merrimack (Inst); Millennium (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); PSMA Development Company (Inst); Roche/Genentech (Inst); Saladax Biomedical (Inst); Sanofi (Inst); Seagen (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Caris Life Sciences; Celgene; Foundation Medicine; Genomic Health; Gilead Sciences; HERON; Incyte; Insys Therapeutics; Lilly; MolecularHealth; Pfizer; Roche/Genentech; Saladax Biomedical; Sanofi
 
Yohann Loriot
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Oncogenex; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Cristina Cruz Zambrano
No Relationships to Disclose
 
Howard A. Burris
No Relationships to Disclose
 
Joseph W. Kim
No Relationships to Disclose
 
Siew-leng Melinda Teng
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Jean-Marie Bruey
Employment - Genentech/Roche
 
Priti Hegde
Employment - Genentech/Roche
 
Oyewale O. Abidoye
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology